These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20693905)

  • 1. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis.
    Wei J; Bhattacharyya S; Varga J
    Curr Opin Rheumatol; 2010 Nov; 22(6):671-6. PubMed ID: 20693905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor γ.
    Luo H; Zhu H; Zhou B; Xiao X; Zuo X
    Mod Rheumatol; 2015 Jul; 25(4):595-602. PubMed ID: 25547017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
    Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A
    Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.
    Wei J; Bhattacharyya S; Jain M; Varga J
    Open Rheumatol J; 2012; 6():103-15. PubMed ID: 22802908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.
    Kökény G; Calvier L; Legchenko E; Chouvarine P; Mózes MM; Hansmann G
    Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):171-179. PubMed ID: 31815758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
    Ruzehaji N; Frantz C; Ponsoye M; Avouac J; Pezet S; Guilbert T; Luccarini JM; Broqua P; Junien JL; Allanore Y
    Ann Rheum Dis; 2016 Dec; 75(12):2175-2183. PubMed ID: 26961294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis.
    Sime PJ
    J Investig Med; 2008 Feb; 56(2):534-8. PubMed ID: 18317437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis.
    Korman B; Marangoni RG; Lord G; Olefsky J; Tourtellotte W; Varga J
    Arthritis Res Ther; 2018 Jul; 20(1):145. PubMed ID: 29996896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists.
    Deng YL; Xiong XZ; Cheng NS
    Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):467-78. PubMed ID: 23060391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of PPARgamma in pulmonary vascular disease.
    Hart CM
    J Investig Med; 2008 Feb; 56(2):518-21. PubMed ID: 18317434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.
    Tseng V; Sutliff RL; Hart CM
    Antioxid Redox Signal; 2019 Oct; 31(12):874-897. PubMed ID: 30582337
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostanoid EP
    Li HH; Hsu HH; Chang GJ; Chen IC; Ho WJ; Hsu PC; Chen WJ; Pang JS; Huang CC; Lai YJ
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L349-L359. PubMed ID: 29146573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis.
    Marangoni RG; Korman BD; Allanore Y; Dieude P; Armstrong LL; Rzhetskaya M; Hinchcliff M; Carns M; Podlusky S; Shah SJ; Ruiz B; Hachulla E; Tiev K; Cracowski JL; Varga J; Hayes MG
    Arthritis Res Ther; 2015 May; 17(1):128. PubMed ID: 25986483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.
    Ren L; Konger RL
    Mol Carcinog; 2019 Sep; 58(9):1589-1601. PubMed ID: 31111568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis.
    Zhang F; Lu Y; Zheng S
    Cell Signal; 2012 Mar; 24(3):596-605. PubMed ID: 22108088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The
    Kavian N; Mehlal S; Jeljeli M; Saidu NEB; Nicco C; Cerles O; Chouzenoux S; Cauvet A; Camus C; Ait-Djoudi M; Chéreau C; Kerdine-Römer S; Allanore Y; Batteux F
    Front Immunol; 2018; 9():1896. PubMed ID: 30177933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.
    Park SJ; Lee YC
    J Asthma; 2008; 45(1):1-8. PubMed ID: 18259989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.